Tissue Regenix has successfully entered the American market.

Tissue Regenix, a biotech spin-out of Leeds University, is celebrating its successful entrance into the US market. The company is now offering its DermaPure product in a market worth $1.4bn annually.

The spin-out’s core technology, dubbed dCell, allows surgeons to use either human or animal tissue to replace damanged human tissue. It had been focusing on entering the US market for the first half of 2014, and has now announced it has established several commercial partnerships for distribution – although it has not disclosed who the distributors are.

Concurrently, the company has announced it is approaching clinical trials of dCell in the EU, and has filed several patents to protect the technology. The trial will focus on the use of dCell in orthopaedics.

Tissue Regenix suffered a pre-tax loss of £3.4m ($5.4m) for the first half of 2014, but the loss had been anticipated.

Antony Odell, chief executive at Tissue Regenix, said: “These milestones maintain our planned progress and build successfully on our strategic focus on the wound care and orthopaedic markets, following the positive data from the UK clinical trial into dCell dermis patches, and our decision to commercialise this product in the USA in 2013. The launch of DermaPure as our first product in the USA represents a significant step for the group.”